<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35076740</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1619-7089</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>European journal of nuclear medicine and molecular imaging</Title><ISOAbbreviation>Eur J Nucl Med Mol Imaging</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic lateral sclerosis with SOD1 mutations shows distinct brain metabolic changes.</ArticleTitle><Pagination><StartPage>2242</StartPage><EndPage>2250</EndPage><MedlinePgn>2242-2250</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00259-021-05668-7</ELocationID><Abstract><AbstractText Label="PURPOSE">Neuropathological data suggest that ALS with SOD1 mutations (SOD1-ALS) is a distinct form of ALS. We evaluated brain metabolic changes characterizing SOD1-ALS as compared to sporadic ALS (sALS), employing <sup>18</sup>fluorodeoxyglucose-positron-emission tomography (<sup>18</sup>F-FDG-PET).</AbstractText><AbstractText Label="METHODS">We included 18 SOD1-ALS patients, 40 healthy controls (HC), and 46 sALS patients without mutations in SOD1, TARDBP, FUS, and C9ORF72, randomly selected from 665 subjects who underwent brain <sup>18</sup>F-FDG-PET at diagnosis between 2008 and 2019 at the ALS Centre of Turin. We excluded patients with frontotemporal dementia. We used the full factorial design in SPM12 to evaluate whether differences among groups exist overall. In case the hypothesis was confirmed, group comparisons were performed through the two-sample t-test model of SPM12. In all the analyses, the height threshold was P &lt; 0.001 (P &lt; 0.05 FWE-corrected at cluster level).</AbstractText><AbstractText Label="RESULTS">The full factorial design resulted in a significant main effect of groups. We identified a relative hypometabolism in sALS patients compared to SOD1-ALS cases in the right precentral and medial frontal gyrus, right paracentral lobule, and bilateral postcentral gyrus. SOD1 patients showed a relative hypermetabolism as compared to HC in the right precentral gyrus and paracentral lobule. As compared to HC, sALS patients showed relative hypometabolism in frontal, temporal, and occipital cortices.</AbstractText><AbstractText Label="CONCLUSION">SOD1-ALS was characterized by a relative hypermetabolism in the motor cortex as compared to sALS and HC. Since promising, targeted, therapeutic strategies are upcoming for SOD1-ALS, our data support the use of PET to study disease pathogenesis and to track its course in clinical trials, in both asymptomatic and symptomatic mutation carriers.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Canosa</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5876-4079</Identifier><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy. antonio.canosa@unito.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, SC Neurologia 1U, Turin, Italy. antonio.canosa@unito.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy. antonio.canosa@unito.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, SC Neurologia 1U, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute of Turin (NIT), Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, SC Neurologia 1U, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasta</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palumbo</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solero</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Pede</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabras</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arena</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Positron Emission Tomography Centre AFFIDEA-IRMET S.p.A., Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zocco</LastName><ForeName>Grazia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casale</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunetti</LastName><ForeName>Maura</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, Department of Clinical Pathology, Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sbaiz</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, Department of Clinical Pathology, Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallone</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, SC Neurologia 1U, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassano</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manera</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, SC Neurologia 1U, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Pagani</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, SC Neurologia 1U, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute of Turin (NIT), Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Nucl Med Mol Imaging</MedlineTA><NlmUniqueID>101140988</NlmUniqueID><ISSNLinking>1619-7070</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">18F-FDG-PET</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">Brain metabolism</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword></KeywordList><CoiStatement>Antonio Canosa, Cristina Moglia, Rosario Vasta, Francesca Palumbo, Luca Solero, Francesca Di Pede, Sara Cabras, Vincenzo Arena, Grazia Zocco, Federico Casale, Maura Brunetti, Luca Sbaiz, Salvatore Gallone, Maurizio Grassano, Umberto Manera, Marco Pagani: no disclosures. Andrea Calvo has received a research grant from Cytokinetics. Adriano Chi&#xf2; serves on scientific advisory boards for Mitsubishi Tanabe, Roche, Biogen, Cytokinetics, Denali Therapeutics, Amylyx, and AveXis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>25</Day><Hour>12</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35076740</ArticleId><ArticleId IdType="pmc">PMC9165265</ArticleId><ArticleId IdType="doi">10.1007/s00259-021-05668-7</ArticleId><ArticleId IdType="pii">10.1007/s00259-021-05668-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet Lond Engl. 2017;390(10107):2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan M, Scott C, Gamarallage MP, Lunn D, Carpenter K, McDonough E, et al. Quantitative patterns of motor cortex proteinopathy across ALS genotypes. Acta Neuropathol Commun. 2020;8(1):98. doi: 10.1186/s40478-020-00961-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-00961-2</ArticleId><ArticleId IdType="pmc">PMC7331195</ArticleId><ArticleId IdType="pubmed">32616036</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, et al. Phase 1&#x2013;2 trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383(2).</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Pagani M, Agosta F, Calvo A, Cistaro A, Filippi M. Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes. Lancet Neurol. 2014;13(12):1228&#x2013;1240. doi: 10.1016/S1474-4422(14)70167-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70167-X</ArticleId><ArticleId IdType="pubmed">25453462</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassubek J, Pagani M. Imaging in amyotrophic lateral sclerosis: MRI and PET. Curr Opin Neurol. 2019;32(5):740&#x2013;746. doi: 10.1097/WCO.0000000000000728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000728</ArticleId><ArticleId IdType="pubmed">31335337</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A, Calvo A, Moglia C, Manera U, Vasta R, Di Pede F, et al. Brain metabolic changes across King&#x2019;s stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography study. Eur J Nucl Med Mol Imaging. 2021;48(4):1124&#x2013;1133. doi: 10.1007/s00259-020-05053-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-05053-w</ArticleId><ArticleId IdType="pmc">PMC8041703</ArticleId><ArticleId IdType="pubmed">33029654</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A, Moglia C, Manera U, Vasta R, Torrieri MC, Arena V, et al. Metabolic brain changes across different levels of cognitive impairment in ALS: a 18 F-FDG-PET study. J Neurol Neurosurg Psychiatry. 2020;23:jnnp-2020&#x2013;jnn323876.</Citation><ArticleIdList><ArticleId IdType="pubmed">33229451</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A, Vacchiano V, D&#x2019;Ovidio F, Calvo A, Moglia C, Manera U, et al. Brain metabolic correlates of apathy in amyotrophic lateral sclerosis: An 18F-FDG-positron emission tomography study. Eur J Neurol. 2021;28(3):745&#x2013;753. doi: 10.1111/ene.14637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14637</ArticleId><ArticleId IdType="pubmed">33175462</ArticleId></ArticleIdList></Reference><Reference><Citation>Cistaro A, Pagani M, Montuschi A, Calvo A, Moglia C, Canosa A, et al. The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. Eur J Nucl Med Mol Imaging. 2014;41(5):844&#x2013;852. doi: 10.1007/s00259-013-2667-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-013-2667-5</ArticleId><ArticleId IdType="pmc">PMC8957062</ArticleId><ArticleId IdType="pubmed">24445987</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Laere K, Vanhee A, Verschueren J, De Coster L, Driesen A, Dupont P, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014;71(5):553&#x2013;561. doi: 10.1001/jamaneurol.2014.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.62</ArticleId><ArticleId IdType="pubmed">24615479</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:5. doi: 10.1080/14660820050515656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820050515656</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wicks P, Abrahams S, Papps B, Al-Chalabi A, Shaw CE, Leigh PN, et al. SOD1 and cognitive dysfunction in familial amyotrophic lateral sclerosis. J Neurol. 2009;256(2):234&#x2013;241. doi: 10.1007/s00415-009-0078-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-0078-0</ArticleId><ArticleId IdType="pubmed">19252762</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatunov A, Al-Chalabi A. The genetic architecture of ALS. Neurobiol Dis. 2021;147:105156. doi: 10.1016/j.nbd.2020.105156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105156</ArticleId><ArticleId IdType="pubmed">33130222</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Moglia C, Canosa A, Manera U, D&#x2019;Ovidio F, Vasta R, et al. ALS phenotype is influenced by age, sex, and genetics: a population-based study. Neurology. 2020;94(8):e802&#x2013;e810. doi: 10.1212/WNL.0000000000008869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008869</ArticleId><ArticleId IdType="pubmed">31907290</ArticleId></ArticleIdList></Reference><Reference><Citation>Pioro EP, Antel JP, Cashman NR, Arnold DL. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology. 1994;44(10):1933&#x2013;1933. doi: 10.1212/WNL.44.10.1933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.44.10.1933</ArticleId><ArticleId IdType="pubmed">7936250</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Jones A, Jivraj N, Knights C, Ellis CM, Burman R, et al. Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale. Amyotroph Lateral Scler Front Degener. 2014;15(3&#x2013;4):279&#x2013;284. doi: 10.3109/21678421.2014.897357.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.897357</ArticleId><ArticleId IdType="pubmed">24720420</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, N&#xe5;gren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36(12):2103&#x2013;2110. doi: 10.1007/s00259-009-1264-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-009-1264-0</ArticleId><ArticleId IdType="pubmed">19838705</ArticleId></ArticleIdList></Reference><Reference><Citation>Della Rosa PA, Cerami C, Gallivanone F, Prestia A, Caroli A, Castiglioni I, et al. A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics. 2014;12(4):575&#x2013;593. doi: 10.1007/s12021-014-9235-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12021-014-9235-4</ArticleId><ArticleId IdType="pubmed">24952892</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani M, Chio A, Valentini MC, Oberg J, Nobili F, Calvo A, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014;83(12):1067&#x2013;1074. doi: 10.1212/WNL.0000000000000792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000792</ArticleId><ArticleId IdType="pubmed">25122207</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, Spinelli EG, Marjanovic IV, Stevic Z, Pagani E, Valsasina P, et al. Unraveling ALS due to SOD1 mutation through the combination of brain and cervical cord MRI. Neurology. 2018;90(8):e707&#x2013;e716. doi: 10.1212/WNL.0000000000005002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005002</ArticleId><ArticleId IdType="pubmed">29367447</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopalan V, Pioro EP. Comparing brain structural MRI and metabolic FDG-PET changes in patients with ALS-FTD: &#x2018;the chicken or the egg?&#x2019; question. J Neurol Neurosurg Psychiatry. 2015;86(9):952&#x2013;958. doi: 10.1136/jnnp-2014-308239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-308239</ArticleId><ArticleId IdType="pubmed">25520437</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR. Abnormal cortical excitability in sporadic but not homozygous D90A SOD1 ALS. J Neurol Neurosurg Psychiatry. 2005;76(9):1279&#x2013;1285. doi: 10.1136/jnnp.2004.054429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2004.054429</ArticleId><ArticleId IdType="pmc">PMC1739803</ArticleId><ArticleId IdType="pubmed">16107368</ArticleId></ArticleIdList></Reference><Reference><Citation>Tondo G, Iaccarino L, Cerami C, Vanoli GE, Presotto L, Masiello V, et al. 11 C-PK11195 PET&#x2013;based molecular study of microglia activation in SOD1 amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7(9):1513&#x2013;1523. doi: 10.1002/acn3.51112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51112</ArticleId><ArticleId IdType="pmc">PMC7480909</ArticleId><ArticleId IdType="pubmed">32762033</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter M, Dennin MA, Walberer M, Backes H, Neumaier B, Fink GR, et al. Neuroinflammation extends brain tissue at risk to vital peri-infarct tissue: a double tracer [ 11 C]PK11195- and [ 18 F]FDG-PET study. J Cereb Blood Flow Metab. 2009;29(6):1216&#x2013;1225. doi: 10.1038/jcbfm.2009.36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2009.36</ArticleId><ArticleId IdType="pubmed">19352400</ArticleId></ArticleIdList></Reference><Reference><Citation>Tondo G, Boccalini C, Caminiti SP, Presotto L, Filippi M, Magnani G, et al. Brain metabolism and microglia activation in mild cognitive impairment: a combined [18F]FDG and [11C]-(R)-PK11195 PET study. J Alzheimers Dis. 2021;80(1):433&#x2013;445. doi: 10.3233/JAD-201351.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-201351</ArticleId><ArticleId IdType="pubmed">33579848</ArticleId></ArticleIdList></Reference><Reference><Citation>Tondo G, Iaccarino L, Caminiti SP, Presotto L, Santangelo R, Iannaccone S, et al. The combined effects of microglia activation and brain glucose hypometabolism in early-onset Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2020;12(1):50. doi: 10.1186/s13195-020-00619-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00619-0</ArticleId><ArticleId IdType="pmc">PMC7193377</ArticleId><ArticleId IdType="pubmed">32354345</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinski A, Franzmeier N, Neitzel J, Ewers M. Alzheimer&#x2019;s disease neuroimaging initiative (ADNI). FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels. Alzheimers Res Ther. 2020;12(1):133. doi: 10.1186/s13195-020-00702-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00702-6</ArticleId><ArticleId IdType="pmc">PMC7574434</ArticleId><ArticleId IdType="pubmed">33076977</ArticleId></ArticleIdList></Reference><Reference><Citation>Meles SK, Renken RJ, Pagani M, Teune LK, Arnaldi D, Morbelli S, et al. Abnormal pattern of brain glucose metabolism in Parkinson&#x2019;s disease: replication in three European cohorts. Eur J Nucl Med Mol Imaging. 2020;47(2):437&#x2013;450. doi: 10.1007/s00259-019-04570-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-019-04570-7</ArticleId><ArticleId IdType="pmc">PMC6974499</ArticleId><ArticleId IdType="pubmed">31768600</ArticleId></ArticleIdList></Reference><Reference><Citation>Mente KP, O&#x2019;Donnell JK, Jones SE, Cohen ML, Thompson NR, Bizzi A, et al. Fluorodeoxyglucose positron emission tomography (FDG-PET) correlation of histopathology and MRI in Prion disease. Alzheimer Dis Assoc Disord. 2017;31(1):1&#x2013;7. doi: 10.1097/WAD.0000000000000188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0000000000000188</ArticleId><ArticleId IdType="pmc">PMC5322151</ArticleId><ArticleId IdType="pubmed">28121634</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Simpson EP, Appel SH. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr Opin Neurol. 2018;31(5):635&#x2013;639. doi: 10.1097/WCO.0000000000000599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000599</ArticleId><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18(2):211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;kkinen S, Chu SA, Lee SE. Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiol Dis. 2020;145:105063. doi: 10.1016/j.nbd.2020.105063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105063</ArticleId><ArticleId IdType="pmc">PMC7572920</ArticleId><ArticleId IdType="pubmed">32890771</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez L, Dube U, Davis AA, Fernandez MV, Budde J, Cooper B, et al. Pleiotropic effects of variants in dementia genes in Parkinson disease. Front Neurosci. 2018;10(12):230. doi: 10.3389/fnins.2018.00230.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00230</ArticleId><ArticleId IdType="pmc">PMC5902712</ArticleId><ArticleId IdType="pubmed">29692703</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobili F, Arbizu J, Bouwman F, Drzezga A, Agosta F, Nestor P, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 2018;25(10):1201&#x2013;1217. doi: 10.1111/ene.13728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13728</ArticleId><ArticleId IdType="pubmed">29932266</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>